Lantern Pharma Inc. (LTRN)
NASDAQ: LTRNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
After hours: 0.8127 0.00%
LTRN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $12.14M
- EPS (TTM)
- -$1.63
- Dividend yield
- None
- 52-week range
- 0.7603 – 4.68
- Day range
- 0.7603 – 0.8301
- Volume / Avg
- 274.07K / 180.42K
- Beta
- —
- Shares outstanding
- 14.94M
52-week range
LTRN stock today
On Oct 9, LTRN ended the session at $0.8127, shedding $0.0173 (2.08%), versus the S&P 500's 0.59% gain. At this level, LTRN sits near the bottom of its 52-week range of $0.7603 to $4.68: 82.6% below the high, set on Oct 8, 2025 and 6.9% above the low. LTRN is down 72.6% year to date, underperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has lost 81.9%.
Lantern Pharma has posted a net loss over the last twelve months (EPS of -$1.63), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Lantern Pharma
Company profileLantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Panna Sharma
- Headquarters
- Dallas, TX
- Employees
- 16
- IPO year
- 2020
- Website
- lanternpharma.com
Analyst forecast
ForecastConsensus (2 analysts)
none
Avg. price target
$17.50+2053.32%
- Strong buy 0
- Buy 2
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Lantern Pharma peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BIVIBioVie Inc. Class A | 1.39 | +8.59% | $12.07M | vs LTRN |
| GTBPGT Biopharma Inc. | 6.68 | +12.27% | $12.05M | vs LTRN |
| BFRGBullfrog AI Holdings Inc. | 0.646 | -6.70% | $11.98M | vs LTRN |
| TPSTTempest Therapeutics Inc. | 0.7601 | -1.29% | $12.84M | vs LTRN |
| ASBPAspire-Lakewood Holdings Inc. | 8.30 | 0.00% | $11.64M | vs LTRN |
| LSTALisata Therapeutics Inc. | 1.06 | -11.67% | $11.45M | vs LTRN |
| PHIOPhio Pharmaceuticals Corp. | 0.9788 | -1.11% | $11.37M | vs LTRN |
| KPRXKiora Pharmaceuticals Inc. | 2.54 | +0.40% | $11.24M | vs LTRN |
Indexes, lists and sector
Lantern Pharma stock FAQ
What is Lantern Pharma's stock price today?
LTRN last traded at $0.8127 as of Oct 9, 4:00 PM EDT, down 2.08% on the day. Prices are delayed at least 15 minutes.
Who is Lantern Pharma's CEO?
Mr. Panna Sharma is the chief executive officer of Lantern Pharma Inc., which has about 16 employees.
What is the LTRN 52-week high?
The 52-week high for LTRN is $4.68 and the 52-week low is $0.7603. The stock is currently 82.6% below its high.